Back to Studies

P1047 / Safety And Immunogenicity Of QHPV In HIV+ Children 7-11 Years Of Age.

Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] L1 Virus-Like Particle [VLP] Vaccine (Gardasil¿) In HIV-Infected Children > 7 to < 12 Years of Age

Study Status

Concluded

Locality

Not Applicable

DAIDS Number

10163

IND Number

BB 13027
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...